Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2023-11-17 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
中国国际金融股份有限公司关于《安徽安科生物工程（集团）股份有限公司第三期限制性股票激励计划》首次授予部分第一个解除限售期解除限售条件成就事项之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is an Independent Financial Advisor Report related to the company's third restricted stock incentive plan, specifically about the first unlocking period conditions being met. It includes detailed explanations of the stock incentive plan, approval procedures, adjustments, and the fulfillment of unlocking conditions. The document is lengthy (9374 characters) and contains substantive financial and procedural information about the stock incentive plan, including approvals, adjustments, and legal opinions. It is not a general announcement or a brief summary but a detailed advisory report. This type of document fits best under the category of Capital/Financing Update (CAP), as it relates to stock incentive plans and equity-related capital matters rather than a full annual report, earnings release, or regulatory filing. Therefore, the classification is CAP with high confidence.
2023-11-17 Chinese
关于延长公司第2期员工持股计划存续期的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the extension of the duration of the company's 2nd employee stock ownership plan. It details the approval by the board and shareholders, references prior meetings and approvals, and provides specifics about the stock plan's terms and extension. The document is relatively short (1600 characters) and focuses on a corporate action related to employee stock plans, not a financial report or earnings release. It is not a report itself but an official announcement of a corporate governance action related to employee share plans. This fits best under the category of Capital/Financing Update (CAP), as it concerns changes in the company's capital structure related to employee stock ownership plans.
2023-11-17 Chinese
关于变更注册资本暨修订《公司章程》的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding changes in registered capital and amendments to the company's articles of association. It details board meeting resolutions about increasing registered capital due to reserved restricted stock grants and decreasing it due to repurchase and cancellation of restricted stock. It also outlines specific amendments to the articles of association reflecting these capital changes. The document is relatively short (1420 characters) and serves as an official announcement of capital changes and related governance document amendments. It does not contain financial statements or detailed financial performance data. Therefore, it fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes.
2023-11-17 Chinese
关于暂不召开股东大会的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (486 characters) from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. It states that the company will temporarily not hold a shareholders' meeting and that the board will issue a separate notice for the meeting. It references resolutions passed by the board and mentions that detailed announcements are available elsewhere. The document does not contain financial data or detailed reports but is an official notice about meeting arrangements and related agenda items. Given the short length and nature of the content, it fits the category of a Regulatory Filing (RNS) rather than a full report or meeting materials.
2023-11-17 Chinese
关于公司第三期限制性股票激励计划部分对象首次授予的第一个限售期解除限售条件成就的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the achievement of the first unlocking conditions for the first restricted stock grant under the company's third restricted stock incentive plan. It details the number of shares to be unlocked, the approval process, legal and financial advisor opinions, and the board and supervisory committee's resolutions. The content focuses on the unlocking of restricted stock and related corporate governance procedures rather than financial results, earnings, or annual reporting. It is not a full financial report, earnings release, or management discussion. It is also not a proxy solicitation or voting result announcement. The document is a formal announcement about a capital-related event (restricted stock unlocking and repurchase) and the related approvals and conditions being met. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (6825 characters) and detailed content support this classification with high confidence.
2023-11-17 Chinese
独立董事关于公司第八届董事会第八次会议相关事项的独立意见
Board/Management Information Classification · 90% confidence The document is an independent directors' opinion on specific company matters related to the third phase of a restricted stock incentive plan, including the lifting of lock-up conditions and the repurchase and cancellation of some restricted stocks. It references compliance with company laws, securities laws, stock exchange rules, and company articles of association. The content focuses on governance and approval of stock incentive plan actions rather than financial results or general management changes. It is not a full annual or interim report, nor an earnings release or capital update. It is a governance-related document expressing independent directors' opinions on specific corporate actions, which fits best under Board/Management Information (MANG) as it relates to board-level decisions and approvals on stock incentive plans and related governance matters.
2023-11-17 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.